Geron (GERN) Total Current Liabilities (2010 - 2026)
Geron recorded quarterly Total Current Liabilities of $73.6 million in Q1 2026, down 34.04% quarter-over-quarter from $111.5 million in Q4 2025, and up 16.71% year-over-year from $63.0 million in Q1 2025.
Geron's Total Current Liabilities history runs 17 years deep, the most recent figure standing at $73.6 million for Q1 2026.
- In Q1 2026, Total Current Liabilities rose 16.71% year-over-year to $73.6 million; the TTM figure through Mar 2026 stood at $73.6 million (up 16.71% YoY), while the FY2025 annual figure was $111.5 million, up 26.32% from the prior year.
- Total Current Liabilities came in at $73.6 million for Q1 2026 at Geron, down from $111.5 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $137.9 million in Q3 2024 to a low of $43.9 million in Q1 2023.
- A 5-year average of $83.5 million and a median of $82.8 million in 2022 frame the typical range for Total Current Liabilities.
- Across the five-year window, Total Current Liabilities soared 180.47% in 2024 and slumped 48.82% in 2025, its largest moves.
- Geron's Total Current Liabilities stood at $76.7 million in 2022, then jumped by 40.91% to $108.1 million in 2023, then decreased by 18.3% to $88.3 million in 2024, then rose by 26.32% to $111.5 million in 2025, then plunged by 34.04% to $73.6 million in 2026.
- According to Business Quant data, Total Current Liabilities over the past three periods registered $73.6 million, $111.5 million, and $87.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,638,563.89 Bn | 1,638,563.89 Bn | - | 16.35 Mn |
| 2 | Alterity Therapeutics | 767,934.24 Bn | 767,934.20 Bn | - | 1.70 Mn |
| 3 | Legend Biotech | 2,937.00 Bn | 2,936.10 Bn | 242.10 Mn | 636.40 Mn |
| 4 | Nanobiotix | 2,282.79 Bn | 2,282.72 Bn | - | 66.94 Mn |
| 5 | Akari Therapeutics | 2,169.69 Bn | 2,169.69 Bn | - | 13.42 Mn |
| 6 | Vertex Pharmaceuticals | 110.41 Bn | 103.16 Bn | 2.59 Bn | 3.88 Bn |
| 7 | Regeneron Pharmaceuticals | 66.44 Bn | 57.69 Bn | 3.31 Bn | 5.11 Bn |
| 8 | Evaxion A | 65.44 Bn | 65.42 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.53 Bn | 36.52 Bn | 959.66 Mn | 1.35 Bn |
| 10 | Geron | 856,799.98 | 856,799.98 | - | 73.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 73.57 Mn |
| Dec 31, 2025 | 111.54 Mn |
| Sep 30, 2025 | 87.71 Mn |
| Jun 30, 2025 | 64.28 Mn |
| Mar 31, 2025 | 63.03 Mn |
| Dec 31, 2024 | 88.30 Mn |
| Sep 30, 2024 | 137.93 Mn |
| Jun 30, 2024 | 103.54 Mn |
| Mar 31, 2024 | 123.16 Mn |
| Dec 31, 2023 | 108.07 Mn |
| Sep 30, 2023 | 89.39 Mn |
| Jun 30, 2023 | 72.57 Mn |
| Mar 31, 2023 | 43.91 Mn |
| Dec 31, 2022 | 76.69 Mn |
| Sep 30, 2022 | 82.81 Mn |
| Jun 30, 2022 | 46.88 Mn |
| Mar 31, 2022 | 46.63 Mn |
| Dec 31, 2021 | 45.52 Mn |
| Sep 30, 2021 | 38.47 Mn |
| Jun 30, 2021 | 37.01 Mn |
| Mar 31, 2021 | 28.55 Mn |
| Dec 31, 2020 | 30.94 Mn |
| Sep 30, 2020 | 24.15 Mn |
| Jun 30, 2020 | 19.14 Mn |
| Mar 31, 2020 | 16.92 Mn |
| Dec 31, 2019 | 28.16 Mn |
| Sep 30, 2019 | 11.86 Mn |
| Jun 30, 2019 | 9.18 Mn |
| Mar 31, 2019 | 6.25 Mn |
| Dec 31, 2018 | 7.55 Mn |
| Sep 30, 2018 | 4.47 Mn |
| Jun 30, 2018 | 4.91 Mn |
| Mar 31, 2018 | 4.39 Mn |
| Dec 31, 2017 | 6.52 Mn |
| Sep 30, 2017 | 5.97 Mn |
| Jun 30, 2017 | 11.27 Mn |
| Mar 31, 2017 | 11.60 Mn |
| Dec 31, 2016 | 7.87 Mn |
| Sep 30, 2016 | 7.32 Mn |
| Jun 30, 2016 | 7.11 Mn |
| Mar 31, 2016 | 6.66 Mn |
| Dec 31, 2015 | 6.63 Mn |
| Sep 30, 2015 | 6.13 Mn |
| Jun 30, 2015 | 40.73 Mn |
| Mar 31, 2015 | 40.63 Mn |
| Dec 31, 2014 | 41.80 Mn |
| Sep 30, 2014 | 7.07 Mn |
| Jun 30, 2014 | 4.76 Mn |
| Mar 31, 2014 | 4.52 Mn |
| Dec 31, 2013 | 7.59 Mn |
| Sep 30, 2013 | 6.84 Mn |
| Jun 30, 2013 | 5.00 Mn |
| Mar 31, 2013 | 6.79 Mn |
| Dec 31, 2012 | 14.15 Mn |
| Sep 30, 2012 | 11.26 Mn |
| Jun 30, 2012 | 11.99 Mn |
| Mar 31, 2012 | 10.27 Mn |
| Dec 31, 2011 | 13.44 Mn |
| Sep 30, 2011 | 10.00 Mn |
| Jun 30, 2011 | 9.27 Mn |
| Dec 31, 2010 | 40.85 Mn |